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ABSTRACT
Vernal keratoconjunctivitis (VKC) is a relatively
rare, chronic form of ocular allergy that can
potentially cause severe visual complications.
Affecting mainly children and young adults, it
is an IgE- and T cell-mediated disease, leading to
a chronic inflammation in which eosinophil,
lymphocyte and structural cell activation are
involved. Treatment of VKC requires a multiple
approach that includes conservative measures
and pharmacologic treatment. Patients and
parents should be made aware of the long
duration of disease, its chronic evolution and
possible complications. Treatment should be
based on the duration and frequency of
symptoms and the severity of corneal
involvement. Mast cell stabilizers and
antihistamines have been proven to be
effective for the treatment of mild to moderate
forms of VKC. In the most severe cases, topical
steroids can be used as rescue medication to
reduce conjunctival and corneal inflammation.
Immunomodulators that have been
investigated for VKC treatment include topical
ocular preparations of cyclosporine A and
tacrolimus. Topical cyclosporine A has been
proven to be effective in the long-term
treatment of VKC, significantly improving
signs and symptoms without significant side
effects.
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INTRODUCTION
Allergic conjunctivitis is a localized allergic
condition frequently associated with rhinitis,
but is often observed as the only or prevalent
allergic phenomenon. Ocular allergy can
involve all of the components of the ocular
surface, including the lid and lid margin,
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conjunctiva and the lacrimal system. The term
allergic conjunctivitis refers to a collection of
hypersensitivity disorders that affect the lid and
conjunctiva. Various clinical forms are included
in the classification of ocular allergy: seasonal/
intermittent allergic conjunctivitis (SAC),
perennial/persistent allergic conjunctivitis
(PAC), vernal keratoconjunctivitis (VKC),
atopic keratoconjunctivitis (AKC) and
drug-induced dermato-conjunctivitis [1].
Corneal involvement is typically restricted to
the two most severe forms of ocular allergy,
vernal keratoconjunctivitis (VKC) and atopic
keratoconjunctivitis (AKC), which requires
particular care in their management.
The current review focuses on the practical
management of VKC, a recurrent, bilateral,
chronic allergic inflammatory disease of the
ocular surface affecting mainly children and
young adults and is characterized by
incompletely identified pathogenic
mechanisms. Several therapeutic measures
are required to control signs and symptoms
of the disease and avoid potential
long-standing or permanent inflammatory
sequelae. Although topical anti-allergic and
anti-inflammatory eye drops are the mainstay
of treatment for VKC, a gold standard
treatment has not yet been established for
this disease.
VERNAL KERATOCONJUNCTIVITIS
VKC is a severe inflammatory disease that
appears in children and adolescents with
seasonal recurrence. It is most often seen in
boys and tends to resolve at puberty. It is a
relatively rare, chronic form of ocular allergy
that can cause severe visual complications [2–4].
VKC is more frequent in warmer, arid, windy
climates, in the Mediterranean area, central
Africa, Japan, India, and South America but is
also reported in North America, China,
Australia, Great Britain, and Sweden. VKC
appears mainly seasonally but can be
perennial, chronic or with acute exacerbations.
It is an IgE- and T cell-mediated allergic reaction
with additional, ill-defined, perhaps
nonspecific, hypersensitivity responses. The
etiology involves a variety of factors, including
environmental allergens, climate, and genetic
predisposition. Cytologic, biohumoral,
immunohistologic, and molecular biologic
studies indicate that VKC is a Th2
lymphocyte-mediated disease. Mast cells and
eosinophils and their mediators play major
roles in the clinical manifestations. In addition
to typical Th2-derived cytokines, Th1-type
cytokines, chemokines, growth factors, and
enzymes are over-expressed [5]. Increased
serum levels of IL-17 and antinuclear
antibodies, together with a high association
with familial history of autoimmune disorders
suggest additional mechanisms involved in the
development of VKC [6, 7]. Tissue remodeling
reactions, papillae formation of different sizes
and shapes, stem cell deficiency, and various
degrees of superficial corneal opacification, are
further consequences of chronic inflammation
[8]. Many elements contribute to this dramatic
response, including epithelial changes,
connective tissue deposition, edema,
inflammatory cell infiltration, and glandular
hypertrophy.
Clinical Forms
It is well known that two VKC populations can
be defined: (1) those with positive test results,
who generally also present with some other
allergic manifestation, such as asthma, rhinitis,
or eczema and (2) those with negative test
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results, and a negative personal and familial
history of atopy.
The disease may present in three clinical
forms: tarsal, limbal and the mixed form. Large
papillae of different shape and size, usually
greater than 1 mm in diameter, on the upper
tarsal conjunctiva characterize the tarsal form,
while Trantas’ dots and infiltrates on the limbus
are typical of the limbal form. The mixed form
is characterized by the presence of both forms in
the same eye. VKC sufferers have a
characteristic ropey, stringy mucous and/or
serous discharge, and corneal complications,
such as superficial punctate keratopathy (SPK),
and shield ulcers are common. Moderate to
intense conjunctival hyperemia, intense
itching, photophobia, mild to moderate
chemosis, foreign-body sensation, and pain are
typical signs and symptoms which may be very
intense upon awakening, causing frequently
what is called the morning misery. While it is
considered a long-term disease with an average
duration of 4–8 years, VKC generally subsides
before or just after puberty [1, 2, 4]. It can persist
or reactivate after puberty, however, a VKC-like
disease has been found in young adults without
any history of allergic disease in childhood [9].
This new clinical entity is characterized by signs
and symptoms similar to the typical VKC.
Allergy test results, cytokine production, and
quality of life are similar to those in pediatric
VKC. It is still unclear if this is a sub-type of VKC
with a later onset or a different clinical entity.
Diagnosis
VKC is not difficult to diagnose by clinical
examination. Trantas’ dots and large
cobblestone papillae are indicative of the
condition [1, 2]. VKC is differentiated from
other ocular allergic conditions, such as SAC,
PAC, AKC, ocular rosacea in children, and
infectious conjunctivitis, through a
comprehensive clinical history and
ophthalmic examination. It is important to
note that while skin test results may be
positive, VKC is not always closely related to
allergen exposure, and climate is an equally
important factor. Conjunctival scrapings or tear
cytology can be useful, revealing increased
leukocytes in the conjunctiva, particularly
eosinophils [1, 2].
MANAGEMENT OF VKC
Understanding and treating VKC has been a
challenge for ophthalmologists, since the
pathogenesis is unclear and anti-allergic
therapy often unsuccessful. VKC is an IgE- and
T cell-mediated disease, leading to a chronic
inflammation in which eosinophil, lymphocyte
and structural cell activation characterize the
conjunctival allergic reaction. Therefore,
measures aimed at stabilization of mast cells or
histamine receptor antagonists alone are
frequently insufficient for controlling
conjunctival inflammation and the frequent
corneal involvement [1, 2]. Currently available
drugs may be merely palliative and do not
extinguish the complex immune process that
initiates and perpetuates the allergic ocular
surface inflammation.
In a meta-analysis of randomized clinical trials
evaluating topical treatments for VKC, only 10 of
21 studies were suitable for statistical analysis,
and the authors concluded that the currently
available topical drugs are effective in treating
acute phases of VKC [10]. However, controlling
VKC signs and symptoms may be a challenge
even for expert ophthalmologists. Because of the
chronicity and severity of the disease, avoidance
of triggers and life-style planning must be
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accompanied by pharmacological treatments:
topical ocular and non-ocular pharmacologic
treatment, systemic pharmacologic treatments
and immunotherapy.
Non-Pharmacologic Management
Patients and parents should be instructed
regarding the nature and duration of the
disease, clinical characteristics and possible
complications. Psychological support may be
necessary in severe cases. The first line of VKC
management, when possible, is the
identification of allergens and avoidance of
those environmental factors that may
exacerbate the disease. Avoiding exposure to
nonspecific triggering factors, such as sun,
wind, and salt water, with the use of
sunglasses, hats with visors, and swimming
goggles should be recommended. Frequent
hand, face, and ear washing should also be
suggested. Cold compresses may help as natural
decongestant. Tear substitutes aid in
stabilization of the tear film, act as an
eyewash, and dilute the concentration of the
allergens and mediators in tears. Eye drops
containing herbal extracts, such as
chamomile-containing preparations, should be
avoided because they may cross-react with
sensitizing allergens [11] (Table 1).
Topical Ocular Pharmacologic Treatment
Pharmacological treatment should be planned
ahead in patients with a history of VKC and
started in the early spring or continued all year,
depending on the allergen exposure and
duration of the symptoms. Currently available
topical drugs for allergic conjunctivitis belong
to several pharmacologic classes (Table 2):
vasoconstrictors, antihistamines, mast cell
stabilizers, ‘dual-acting’ agents (with
antihistaminic and mast cell stabilizing
properties), non-steroidal anti-inflammatory
agents, corticosteroids and immunosuppressive
drugs.
Mast Cell Stabilizers
Mast cell stabilizers are the first-line drugs for
VKC. Topical mast cell stabilizers are generally
safe and have minimal ocular side effects,
although there may be some tolerability
concerns, since transient burning or stinging
may occur upon application. Several studies
have demonstrated the efficacy of 2% and 4%
sodium cromoglicate (DSCG, cromolyn),
nedocromil sodium 2%, lodoxamide
tromethamine 0.1%, and spaglumic acid 4%
[12–14]. The recommended dosing schedule is
4–6 times daily, with a loading period of at least
7 days and an onset of activity after as much as
2 weeks. DSCG alone has limited effects in the
treatment of VKC and is less well tolerated than
newer anti-allergic compounds. Nedocromil
appears to be more potent than DSCG [15],
acting on multiple cells involved in allergic
Table 1 Patient education and preventive measures to
improve the management of vernal keratoconjunctivitis
VKC is a chronic, recurrent condition that usually
improves by adulthood
Avoid rubbing itchy eyes, as this makes
the condition worse
Avoid provocative nonspeciﬁc triggers such as sun,
wind, and salt water, that exacerbate the condition,
using sunglasses, hats with visors, swimming goggles
where necessary
Avoid contact with commonly known allergens
Application of cold compresses and preservative-free
artiﬁcial tears help to provide symptomatic relief
Hands, face and hair should be washed frequently to
reduce exposure to allergens
Plan to take vacations in suitable climates
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inflammation, including eosinophils,
neutrophils, macrophages, mast cells,
monocytes, and platelets.
Lodoxamide has long been available for the
treatment of VKC. Its mechanism of action is
thought to be similar to that of DSCG, since it was
shown to prevent tryptase release [16].
Lodoxamide was shown to be more effective
than DSCG for the inhibition of eosinophil
activation, evaluated by measuring tear
Table 2 Topical ocular allergy medications for the treatment of vernal keratoconjunctivitis



















Relief of signs and
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Frequently does not provide complete












Risk for long-term side effects
No mast cell stabilization
Potential for inappropriate patient
use
Requires close monitoring
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eosinophil cationic protein ECP before and
after therapy [17], suggesting that lodoxamide
has an effect on eosinophil activation.
Inhibition of eosinophil activation and
degranulation is the proposed mechanism for
its efficacy against corneal signs such as
keratitis and shield ulcers in severe allergic
disease [17]. Lodoxamide was shown to be
superior to placebo [18] and N-acetyl aspartyl
glutamic acid (NAAGA) for treatment of VKC
[19]. The recommended dosing schedule is four
times daily. Lodoxamide may be used
continuously for 3 months in children older
than 2 years of age.
NAAGA 6% has been widely used in Europe
as topical eye drops in the treatment of VKC
[20]. NAAGA is known to inhibit leukotriene
synthesis, histamine release by mast cells, and
complement-derived anaphylatoxin
production. This anti-allergic compound was
also shown to directly inhibit leukocyte
adhesion to endothelial cells induced by
proinflammatory stimuli, and abrogates tumor
necrosis factor a-induced expression of
adhesion molecules on granulocytes and
endothelial cells [21]. These pharmacological
properties confer a potential anti-inflammatory
activity.
Antihistamines
Antihistamines act via histamine receptor (HR)
antagonism to block the inflammatory effects of
endogenous histamine and prevent or relieve
the associated signs and symptoms. Most
antihistamines used in the treatment of allergy
are H1 receptor antagonists, although some
agents may have affinity for other receptor
subtypes [22]. H2 antagonists have been shown
to modulate both cell growth and migration
[22]. Ocular drugs with antihistaminic activity
may offer therapeutic advantages to patients
with allergic conjunctivitis, including VKC, by
inhibiting proinflammatory cytokine secretion
from conjunctival epithelial cells [23]. The first-
generation antihistamines pheniramine and
antazoline have a long safety record, but are
known for their burn upon instillation, the
rapid onset and disappearance of their effects,
and their limited potency [24]. These are still
available in over-the-counter products,
particularly in combination with
vasoconstrictors.
The newer antihistamines are still H1
antagonists, but have a longer duration of
action (4–6 h), and are better tolerated than
their predecessors. These include levocabastine
hydrochloride 0.5% and emedastine difumarate
0.05%.
Levocabastine 0.05% eye drops alone,
instilled four times daily for 3 months, was
effective, safe, and well tolerated by patients
with VKC; however, it was less effective than
lodoxamide [25] or NAAGA [20]. Interestingly,
in an animal model, levocabastine reduced
the clinical aspects of the late-phase reaction
and the conjunctival expression of
alpha(4)beta(1) integrin by reducing
infiltration of eosinophils [26].
Emedastine 0.05% appears to be more potent
and selective than levocabastine [27, 28].
Indeed, in direct comparison with
levocabastine, emedastine proved significantly
more effective in alleviating signs of seasonal
allergic conjunctivitis [27, 28]. No specific
studies in VKC have been performed.
A meta-analysis of randomized clinical trials
in VKC showed a large number of studies (20)
evaluated the efficacy of common anti-allergic
eye drops (levocabastine, lodoxamide,
mipragoside, NAAGA, nedocromil sodium,
DCG). Among these, lodoxamide appeared to
be the most effective [10].
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Topical Antihistamines with Multiple
Anti-Inflammatory Activities
New antihistamines that combine mast cell
stabilizing properties and histamine receptor
antagonism, such as alcaftadine, azelastine,
bepotastine, epinastine, ketotifen, and
olopatadine, are presently available and show
evident benefits in treating all forms of ocular
allergy. The advantage offered by these agents is
the rapidity of symptomatic relief given by
immediate histamine receptor antagonism,
which alleviates itching and redness, coupled
with the long-term disease-modifying benefit of
mast cell stabilization. All of these medications
are well tolerated and none are associated with
significant ocular drying effects. Although
widely used in the treatment of VKC, specific
studies in VKC are very few. Olopatadine and
ketotifen have shown efficacy in relieving signs
and symptoms in patients with VKC. These two
drugs may have also anti-inflammatory
properties, reducing eosinophil activation and
cytokine release. A significant difference in
favor of ketotifen-treated patients has being
shown in a single-center, simple-masked study
comparing these two drugs [29]. However, both
drugs were efficient and safe relieving the main
symptoms and signs of VKC, including itching,
tearing, conjunctival hyperemia, mucous
discharge and photophobia. Olopatadine
hydrochloride 0.1% was effective for relieving
the signs and symptoms of VKC and reducing
the number of goblet cells during treatment
[30].
Decongestants are a useful adjunctive
therapy to mast cell stabilizers and/or
antihistamines in mild and moderate forms of
VKC, or in adult patients who have
demonstrated a notable improvement in
symptomatology after adolescence. However,
topical decongestants do not reduce the
allergic response because they do not
antagonize any of the mediators of allergic
inflammation. Burning or stinging on
instillation is a common side effect. Prolonged
use of topical decongestants, as well as the
discontinuation of these agents following
prolonged use, can lead to rebound hyperemia
and conjunctivitis medicamentosa [31]. These
events are usually associated with topical
first-generation antihistamines such as




Generally NSAIDS employed in ocular allergy
treatment inhibit both cyclooxygenase (COX)-1
and COX-2 enzymes. Ketorolac, diclofenac, and
pranoprofen, may also be valid alternatives to
steroids, since they have a proven effect on
itching, intercellular adhesion molecule-1
expression, and tear tryptase levels [32].
Indomethacin 1% [33], ketorolac 0.5% [34],
and diclofenac 0.1% have shown effectiveness
in the treatment of VKC [35].
Topical Corticosteroids
Moderate to severe VKC needs repeated
topical steroid treatment to downregulate
conjunctival inflammation. Persistent severe
symptoms, thick mucous discharge with
moderate to severe corneal involvement,
numerous and inflamed limbal infiltrates
and/or giant papillae, indicate a need for
corticosteroids. However, corticosteroids
should be avoided as the first line of defense
in the treatment of VKC. If steroids are used,
those with low intraocular absorption, such as
hydrocortisone, clobetasone, desonide,
fluorometholone, loteprednol, difluprednate
and rimexolone, should be used first. Dosages
are chosen based on the inflammatory state of
the eye, with therapy prescribed in pulses of
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3–5 days. Loteprednol etabonate is usually
indicated for 7–8 days in the treatment of
the acute phase. Prednisolone,
dexamethasone, or betamethasone should be
used only when the above-mentioned
first-choice steroids have proven ineffective.
Steroid–antibiotic combination eye drops
should be avoided, as VKC is an allergic
inflammation, rather than an infection.
Corticosteroids should not be recommended
for long-term use because of possible ocular
adverse effects, including increases in
intraocular pressure (IOP), induction or
exacerbation of glaucoma, formation of
cataracts, delayed wound healing, and
increased susceptibility to infection or
superinfection. These adverse effects depend,
in part, on the structure, dose, duration of
treatment and gender disposition [36]. In fact,
following daily administration of
corticosteroids for 4–6 weeks, approximately
one-third of the normal population will be
‘‘high or moderate responders’’ with an
increase in IOP of between 6 and 15 mm Hg
[36]. Forty-one of 145 (28.3%) patients with
severe VKC in a Singapore case series
developed a corticosteroid response, of
which eight (5.5%) progressed to glaucoma
[37]. Six of these patients (n = 8 eyes) required
trabeculectomy/mitomycin-C. The main risk
factor for trabeculectomy was a greater
increase in IOP from baseline, which was
independent of potential confounders such as
type and duration of corticosteroid use [38].
Calcineurin Inhibitors and Other
Immunomodulators
Cyclosporine A (CsA) is effective in controlling
VKC-associated ocular inflammation by
blocking Th2 lymphocyte proliferation and
interleukin-2 production. It inhibits histamine
release from mast cells and basophils through a
reduction in IL-5 production, and may reduce
eosinophil recruitment and effects on the
conjunctiva and cornea [39]. CsA is lipophilic
and thus must be dissolved in an alcohol-oil
base [39]. Unavailability of a commercial
preparation of topical CsA, technical
difficulties in dispensing eye drops and legal
restrictions on its topical use in many countries,
preclude its widespread use for VKC treatment.
The 2% formulation has the longest track
record, but lower concentrations (1%, 0.5%,
and 0.05%) have been used and shown to be
effective. So far, there is no general consensus
regarding the minimum effective concentration
of CsA. Only the 0.05% formulation is
commercially available for the treatment of
dry eye.
After long cycles of treatment, CsA has a
marked steroid-sparing effect, potentially
allowing control of symptomatology without
steroids [40]. When necessary, additional
topical steroids can be used in short cycles.
Systemic absorption of CsA was not detectable
by clinical laboratory methods. Burning and
irritation are frequent side effects. Treatment
can be prescribed seasonally or perennially,
reducing doses in the non-active phases of the
disease. Adverse events, such as bacterial or viral
infections are rare, while IOP changes have not
been reported.
CsA 1% or 2% emulsion in castor or olive oil
instilled four times daily can be considered for
treatment of moderate to severe VKC and can
serve as a good alternative to steroids [39, 41].
After 2 weeks, CsA 1% four times daily
significantly reduced signs and symptoms and
tear levels of ECP in a group of VKC patients
[42].
CsA 1% was reported to be the minimum
effective concentration in the treatment of
shield ulcers, with recurrence observed at
lower concentrations [43]. In a randomized,
80 Ophthalmol Ther (2013) 2:73–88
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controlled trial, the effects of CsA 0.05% were
similar to placebo [44]. Conversely, in another
study, CsA 0.05% decreased the severity of
symptoms and clinical signs significantly after
6 months and the need for steroids was reduced,
suggesting that CsA at low doses is an effective
steroid-sparing agent in VKC [45]. In a clinical
prospective and observational study in 594
patients, CsA 0.1% was shown to be effective
and safe for the treatment of VKC [46]. A recent
systematic review and meta-analysis study
suggests that topical CsA is effective and safe
for the treatment of VKC, since signs and
symptoms significantly improve after
treatment, regardless of the CsA dosage [47].
A randomized, controlled two-year crossover
study demonstrated the safety and efficacy of
CsA 0.05% for long-term prevention of VKC
relapses [40]. Patients treated with ketotifen had
a risk of recurrences 2.4 times higher than
patients treated with CsA. In addition, CsA
significantly improved itching, photophobia
and conjunctival hyperemia scores in
comparison with ketotifen. These data are of
great importance for the long-term
management of pediatric patients at risk of
visual impairment, whether due to steroid
abuse or to continued recurrences of acute
inflammation [40].
Tacrolimus is a potent drug, similar to CsA in
its mode of action, but chemically distinct. A
tacrolimus skin ointment is licensed for the
treatment of moderate to severe atopic eyelid
diseases and may have secondary benefits for
AKC [48–50]. Conjunctival application of
tacrolimus ointment 0.03% and 0.1% were
effective, well tolerated, and safe in the
treatment of severe allergic conjunctivitis [49,
51]. In a multicenter, randomized,
double-masked, placebo-controlled clinical
trial, tacrolimus ophthalmic suspension 0.1%
was shown to be effective in treating severe
allergic conjunctivitis. Patients were treated
twice daily for 4 weeks. Objective signs,
subjective symptoms, giant papillae and
corneal involvement were significantly
improved. The most frequent tacrolimus-
related adverse event was ocular irritation [52].
In the same study it is also reported that the dose
of tacrolimus was based on the results from a
previous dose-ranging study in which
tacrolimus ophthalmic suspension 0.01%,
0.03%, and 0.1% were tested. Since 0.1%
showed stronger improvement and similar
safety profile compared with 0.01% and 0.03%,
the 0.1% was considered an optimal dose.
Documentation on the quality, safety and
efficacy of the different preparations used in the
different clinical reports will be necessary before
tacrolimus is granted orphan medication status
for VKC.
A prospective double-masked randomized
comparative trial comparing the efficacy of
0.1% tacrolimus ophthalmic ointment with
CsA 2% showed that both were equally
effective in the treatment of VKC [53].
Short-term, low-dose, topical mitomycin-C
0.01% has been considered for treating acute
exacerbations in patients with severe VKC
refractory to conventional treatment [54]. A
significant decrease in signs and symptoms
compared with the placebo group was shown at
the end of the 2-week treatment period.
Unavailability of commercial topical
preparations, the short duration of studies, and
the lack of data on the safety profile and long-term
outcomes are major limitations in recommending
mitomycin for the treatment of VKC.
Topical Non-Ocular Pharmacologic
Treatment
The efficacy of intranasal corticosteroids in
treating allergic nasal symptoms is well
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established. Recent data show a promising effect
of intranasal corticosteroids on ocular
symptoms of allergic rhinoconjunctivitis [55].
At the moment, no studies in VKC have been
performed or reported in the literature. The
mechanism by which an intranasal
corticosteroid reduces ocular allergic
symptoms has been under investigation; some
effects on both the reflex neural activity and the
local inflammation, facilitating nasolacrimal
drainage, have been proposed [56].
Meta-analysis studies showed that there is no
significant difference in improvement of eye
symptoms between intranasal corticosteroids
and oral antihistamines [57] including
non-sedating antihistamines. Thus, in VKC
patients with associated nasal symptoms, nasal
corticosteroids may be beneficial.
Systemic Pharmacologic Treatment
Systemic treatment with oral antihistamines or
antileukotrienes can reduce the severity of
flare-ups and generalized hyper-reactivity. First-
generation H1 receptor antagonists may provide
some relief of ocular itching, but are sedating and
have anticholinergic effects such as dry mouth,
dry eye, blurred vision and urinary retention.
Second-generation antihistamines offer the same
efficacy as their predecessors, but with a low-
sedating profile and lack of anticholinergic
activity. These drugs include acrivastine,
cetirizine, ebastine, fexofenadine, loratadine and
mizolastine. However, even their use has been
associated with drying effects, particularly of the
ocular surface [58]. Desloratadine and
levocetirizine are considered a subsequent
evolution of these second-generation agents and
are preferred over first-generation antihistamines
for the treatment of allergic conjunctivitis [59].
Aspirin 0.5–1 g per day has been shown as a
steroid-sparing factor in the treatment of VKC
[60]; however, it should be used with caution
because of the well-known possible side effects.
In severe cases, systemic treatment with
T-lymphocyte signal transduction inhibitors
such as CsA or tacrolimus may ameliorate
both the dermatologic and ocular
manifestations in severe patients who are
refractory to conventional treatment [61].
Omalizumab, an anti-IgE recombinant,
humanized, non-anaphylactogenic antibody,
directed against the receptor-binding domain
of IgE, may be used in VKC patients with high
levels of total serum IgE [62].
Specific Immunotherapy
Allergen-specific immunotherapy (SIT) is
indicated only when a clearly defined systemic
hypersensitivity to identified allergens exists.
The choice of the allergen to be employed for
SIT should be made in accordance with the
combination of clinical history and results of
skin prick test and specific serum IgE. Since the
development of non-invasive formulations with
better safety profiles, there is an increasing
tendency to prescribe sublingual
immunotherapy (SLIT) in young patients. A
systematic review and meta-analysis of
double-blind, placebo-controlled randomized
controlled trials confirmed that SLIT reduces
significantly ocular symptom scores in patients
with allergic conjunctivitis with or without
rhinitis [63]. The SIT treatment in IgE-positive
patients with VKC was more effective than
topical treatment in improving clinical
symptoms and reducing total serum IgE [64].
Surgical Treatment
Supratarsal injection of either a short- or
intermediate-acting corticosteroid has been
proposed as a therapeutic approach to treating
82 Ophthalmol Ther (2013) 2:73–88
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patients with refractory VKC [65]. Although
significant symptomatic and clinical
improvements have been reported, persistent
increase in IOP occurred in one of 12 VKC
patients [65].
Surgical removal of corneal plaques is
recommended to alleviate severe symptoms
and to allow for corneal re-epithelization.
Giant papillae excision with intraoperative
0.02% mitomycin-C followed by CsA topical
treatment may be indicated in cases of
mechanical pseudoptosis or the presence of
coarse giant papillae and continuous active
disease [66, 67].
Cryotherapy and/or excision of giant papillae
should otherwise be avoided because these
measures treat only the complications and not
the underlying disease, and may induce
unnecessary scarring. Amniotic membrane
transplantation (AMT) following keratectomy
has been described as a successful treatment for
deep ulcers, in cases with slight stromal
thinning [68]. The presence of residual
membrane under the epithelium may affect
postoperative corneal transparency. The
treatment algorithm for corneal complication
can be based on the Cameron clinical grading of
shield ulcers [69]: Grade 1, ulcers received
medical therapy alone; Grade 2 and Grade 3
ulcers received either medical therapy alone or
medical therapy combined with debridement,
AMT, or both. Using this approach, it was shown
that Grade 1 ulcers respond well to medical
therapy alone; Grade 2 ulcers occasionally may
require additional debridement or AMT; Grade 3
ulcers are frequently refractory to medical
therapy and require debridement and AMT for
rapid re-epithelialization [70] .
Significant limbal stem cell deficiency as a
complication of severe and persistent limbal
inflammation has been treated with stem cell
transplantation [71, 72].
These and other more invasive procedures
such as oral mucosal grafting should be avoided
or considered only by ophthalmology experts in
VKC management.
PRACTICAL MANAGEMENT OF VKC
Treatment of VKC requires a multi-pronged
approach that includes conservative measures
and the use of drugs, as summarized in Table 3.
Close collaboration between ophthalmologists,
allergists and pediatricians is recommended.
Patients and parents should be made aware of
the long duration of disease, its chronic
evolution and possible complications.
It is recommended to use a clinical grading
system to identify the more severe forms of VKC
that are at higher risk of recurrences, corneal
ulceration, and worsened final visual outcome
[73]. A simple grading system has been
proposed to formulate global guidelines for
treating VKC (Table 4) [73–75].
The selection of a drug from the many
available options is also based on geographical
area, personal experience and preference of
the treating physician, since there is no
standard treatment and a lack of evidence to
support choice of drug in the management of
VKC.
Topical administration of mast cell
stabilizers, with preference for those which
have anti-eosinophil effects such as NAAGA
and lodoxamide, should be started at the onset
of the allergic symptoms and used continuously
throughout the season. If monotherapy with
mast cell stabilizers is not enough to prevent the
symptoms, antihistamines or multiple-acting
drugs such as olopatadine and ketotifen, 2–4
times a day should be added and continued for
the entire season. Frequent instillations may be
inconvenient, however, no significant side
effects of these drugs have been reported with
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short- or long-term use. Preservative-free
formulations should be recommended.
NSAIDs such as ketorolac, diclofenac and
pranoprofen may be considered as steroid-
sparing options. However, in clinical practice
they have limited use in VKC management.
Systemic treatment with oral antihistamines or
antileukotrienes can reduce the severity of
ocular flare-ups and the nonspecific hyper-
reactivity typical of these patients. They
Table 3 Summary of the practical management of VKC
Make an accurate diagnosis
Educate on avoidance of the offending allergens and nonspeciﬁc triggers
(use sunglasses, hats with visors, and swimming goggles)
Stress the importance of non-pharmacologic treatments (lubricants, lid hygiene, cold compresses)
Two or more topical, complementary drugs must be used in combination
(mast cell stabilizers ? antihistamines or multiple action components)
Recommend an adequate frequency of instillation of topical drugs (4–6 times per day)
Warn against use and abuse of decongestant/vasoconstrictors
Recommend systemic antihistamines to reduce hyper-reactivity
Use topical corticosteroid formulations as pulsed therapy (3–5 days) to reduce ﬂare-ups
Corticosteroids must be used in case of moderate to severe corneal epitheliopathy and ulcers
Avoid the continuous use and/or abuse of steroids
Avoid corticosteroids as ﬁrst-line treatment of VKC
Topical CsA can be considered in moderate to severe VKC and can be steroid-sparing
Removal of corneal plaques is the only surgical procedure recommended in cases of corneal complications
Speciﬁc immune therapy is indicated only if extra-allergic manifestations are also present,
when a speciﬁc offending allergen is clearly identiﬁed and clinically related to ocular manifestations
Table 4 Clinical grading of vernal keratoconjunctivitis and therapeutical approach
Grade Clinical ﬁndings Treatment
0 (quiescent) Absence of symptoms No treatment
1 (mild) Presence of symptoms with no corneal
involvement
Anti-allergic eye drops daily
2 (moderate) Presence of symptoms associated with
photophobia with no corneal involvement
Combined anti-allergic eye drops daily
3 (severe) Presence of symptoms associated with
photophobia and mild to moderate SPK
Anti-allergic eye drops daily with pulsed
low-dose topical steroid
4 (very severe) Presence of symptoms associated with
photophobia and diffuse SPK or corneal ulcer
Pulsed high-dose topical steroid with
eventual surgical removal of corneal plaque
SPK superﬁcial punctate keratopathy
Modiﬁed from [73, 75]
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should be started at the onset of symptoms and
used continuously throughout the allergic
season.
Moderate to severe VKC may require
repeated topical steroid treatment to
downregulate conjunctival inflammation and
reduce cellular infiltrate. ‘‘Soft corticosteroids’’
may be considered preferentially as the first
corticosteroid preparations to be used. Dosages
are chosen based on the inflammatory state. An
instillation frequency of 4 times per day for
5–10 days is recommended. Prednisolone,
dexamethasone or betamethasone should be
used as a second-line choice, or as first-line
treatment in the most severe cases. A ‘‘pulsed’’
treatment of 3–5 days, in addition to the
continuous use of mast cell stabilizers and
topical antihistamines, is recommended. The
use of ointment at night-time may be helpful in
children when opening the eyes in the morning
is difficult because of photophobia due to the
epitheliotoxicity of released mediators while
the eyes are closed.
CsA 1% or 2% can be considered for
treatment of moderate to severe VKC. It
decreases the severity of signs and symptoms
and the need for steroids. No significant side
effects, except for a burning sensation during
administration, have been reported [39]. No
randomized studies on dose–effect differences
have been published. In clinical practice, one
drop of CsA 1% from 2 to 4 times a day,
depending on the severity of signs and
symptoms, is effective for controlling the
disease during seasonal exacerbations.
Treatment can be suspended during winter
until the first exacerbation of the new season.
Adult patients respond better to CsA compared
with any other therapeutic regimen [9].
If a patient does not respond to CsA, topical
tacrolimus can be considered. Several
experiences with tacrolimus have been
reported using different preparations and
concentrations. It seems to be more effective
than CsA, and also effective in patients
refractory to CsA. Randomized trials of topical
tacrolimus are needed.
Corneal complications should be carefully
monitored and anti-inflammatory therapy
adjusted; in these cases, steroids should be used,
since the pathogenesis of the ulcer is strictly
immune-mediated. Corticosteroids are preferred
over CsA, since they are more effective in
inhibiting the inflammatory component of
corneal damage (i.e., eosinophil- and neutrophil-
liberated epithelial toxic mediators) [2].
Severe cases that do not respond to any of
these topical therapies may require treatment
with systemic corticosteroids (prednisone
1 mg/kg per day) for a short period of time.
If a systemic hypersensitivity to identified
allergens exists, specific immunotherapy may
be considered.
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